Literature DB >> 17043648

Tissue transglutaminase expression promotes cell attachment, invasion and survival in breast cancer cells.

L S Mangala1, J Y Fok, I R Zorrilla-Calancha, A Verma, K Mehta.   

Abstract

Distant metastasis is frequently observed in patients with breast cancer and is a major cause of cancer-related deaths in these patients. Currently, very little is known about the mechanisms that underlie the development of the metastatic phenotype in breast cancer cells. We previously found that metastatic breast cancer cells express high levels of tissue transglutaminase (TG2), but established no direct link between TG2 and metastasis. In this study, we hypothesized that TG2 plays a role in conferring the metastatic phenotype to breast cancer cells. The results obtained suggested that increased expression of TG2 in breast cancer cells contributes to their increased survival, invasion and motility. We further found that TG2 protein in a metastatic breast cancer MDA-MB231 cells was present on the cell surface in close association with integrins beta1, beta4 and beta5. Downregulation of endogenous TG2 by small interfering RNA inhibited fibronectin (Fn)-mediated cell attachment, survival and invasion. Conversely, ectopic expression of TG2 augmented invasion of breast cancer cells and attachment to Fn-coated surfaces. We conclude that TG2 expression in breast cancer cells plays an important role in the development of the metastatic phenotype.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17043648     DOI: 10.1038/sj.onc.1210035

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  79 in total

1.  Pre- and post-translational regulation of osteopontin in cancer.

Authors:  Pieter H Anborgh; Jennifer C Mutrie; Alan B Tuck; Ann F Chambers
Journal:  J Cell Commun Signal       Date:  2011-04-26       Impact factor: 5.782

Review 2.  Transglutaminase 2: a molecular Swiss army knife.

Authors:  Soner Gundemir; Gozde Colak; Janusz Tucholski; Gail V W Johnson
Journal:  Biochim Biophys Acta       Date:  2011-10-10

3.  Transglutaminase 2 as a novel activator of LRP6/β-catenin signaling.

Authors:  S Deasey; D Nurminsky; S Shanmugasundaram; F Lima; M Nurminskaya
Journal:  Cell Signal       Date:  2013-08-29       Impact factor: 4.315

4.  A novel mechanism by which tissue transglutaminase activates signaling events that promote cell survival.

Authors:  Lindsey K Boroughs; Marc A Antonyak; Richard A Cerione
Journal:  J Biol Chem       Date:  2014-02-25       Impact factor: 5.157

Review 5.  Cellular functions of tissue transglutaminase.

Authors:  Maria V Nurminskaya; Alexey M Belkin
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

6.  EGF potentiated oncogenesis requires a tissue transglutaminase-dependent signaling pathway leading to Src activation.

Authors:  Bo Li; Marc A Antonyak; Joseph E Druso; Le Cheng; Alexander Yu Nikitin; Richard A Cerione
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

7.  Prognostic role of tissue transglutaminase 2 in colon carcinoma.

Authors:  María Jesús Fernández-Aceñero; Sofía Torres; Irene Garcia-Palmero; Cristina Díaz Del Arco; J Ignacio Casal
Journal:  Virchows Arch       Date:  2016-09-13       Impact factor: 4.064

8.  Inhibition of AR-mediated transcription by binding of Oct1 to a motif enriched in AR-occupied regions.

Authors:  Unnati Jariwala; Jon P Cogan; Li Jia; Baruch Frenkel; Gerhard A Coetzee
Journal:  Prostate       Date:  2009-03-01       Impact factor: 4.104

9.  Tissue transglutaminase 2 as a biomarker of cervical intraepithelial neoplasia (CIN) and its relationship to p16INK4A and nuclear factor kappaB expression.

Authors:  Ruchi Gupta; Radhika Srinivasan; Raje Nijhawan; Vanita Suri
Journal:  Virchows Arch       Date:  2009-11-25       Impact factor: 4.064

Review 10.  Transglutaminase is a tumor cell and cancer stem cell survival factor.

Authors:  Richard L Eckert; Matthew L Fisher; Dan Grun; Gautam Adhikary; Wen Xu; Candace Kerr
Journal:  Mol Carcinog       Date:  2015-08-10       Impact factor: 4.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.